Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

Ruxu You,1,* Jinyu Liu,2,* David Bin-Chia Wu,3 XinYu Qian,4 Boxiang Lyu,5 Yu Zhang,1 Nan Luo4 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Department of Pharmacy, Tongji Hospital,...

Full description

Bibliographic Details
Main Authors: You R, Liu J, Wu DBC, Qian X, Lyu B, Zhang Y, Luo N
Format: Article
Language:English
Published: Dove Medical Press 2019-12-01
Series:Cancer Management and Research
Subjects:
economic analysis
incremental cost-effectiveness ratio
nsclc
eger mutation testing
afatinib
Online Access:https://www.dovepress.com/cost-effectiveness-analysis-of-egfr-mutation-testing-and-afatinib-vers-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/cost-effectiveness-analysis-of-egfr-mutation-testing-and-afatinib-vers-peer-reviewed-article-CMAR

Similar Items